Phase I trials start for anti-angiogenic eye drop therapy for AMD

Article

Athenagen Inc. began a phase I clinical trial of mecamylamine (ATG003), its eye drop therapy for age-related macular degeneration (AMD). Animal models showed efficacy of ATG003 as an alternative to current AMD therapies, which require needle injections directly in the eye. The randomized, placebo-controlled, ascending dose clinical trial is designed to evaluate ocular tolerability and safety for up to 14 days.

Athenagen Inc. began a phase I clinical trial of mecamylamine (ATG003), its eye drop therapy for age-related macular degeneration (AMD). Animal models showed efficacy of ATG003 as an alternative to current AMD therapies, which require needle injections directly in the eye. The randomized, placebo-controlled, ascending dose clinical trial is designed to evaluate ocular tolerability and safety for up to 14 days.

ATG003 is a novel anti-angiogenic agent that inhibits endothelial nicotinic acetylcholine receptors. The therapy has been shown to decrease angiogenesis as well as vascular permeability.

“This is a significant advancement in the development of new medications for AMD,” said W. Scott Harkonen, MD, Athenagen president and CEO. “We expect to generate data from our phase I study by the end of the year and plan to move directly into a larger efficacy study in the first part of 2007.”

Recent Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.